Literature DB >> 989091

Randomized prospective trial of continuous vs intermittent heparin therapy.

R L Glazier, E B Crowell.   

Abstract

Forty-one patients with clinical indications for heparin therapy were randomized to receive continuous intravenous heparin sodium therapy or intermittent (four-hourly bolus) heparin therapy, with control by the activated partial thromboplastin time. Seven of 21 patients receiving intermittent therapy had major bleeding episodes, whereas none of the 20 patients receiving continuous heparin therapy had major bleeding (P = .005). One patient on continuous therapy had a pulmonary embolus, while none on intermittent therapy had recurrent thromboembolism. Two heavily bleeding patients on intermittent therapy were switched to continuous treatment after bleeding was controlled. The use of continuous heparin therapy appears significantly safer with regard to hemorrhagic complications than the use of intermittent therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989091

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

Review 1.  Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

Authors:  Lindsay Robertson; James Strachan
Journal:  Cochrane Database Syst Rev       Date:  2017-02-14

Review 2.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

3.  The principles and practice of anticoagulant therapy.

Authors:  C J Carter
Journal:  Can Fam Physician       Date:  1987-11       Impact factor: 3.275

4.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

5.  Indications and techniques for the use of heparin in the treatment of thromboembolism.

Authors:  D Deykin
Journal:  World J Surg       Date:  1978-01       Impact factor: 3.352

6.  The economics of general thromboembolic prophylaxis.

Authors:  D Bergqvist; S Jendteg; B Lindgren; T Mätzsch; U Persson
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

Review 7.  Anticoagulants in venous thromboembolism.

Authors:  A Fennerty; I A Campbell; P A Routledge
Journal:  BMJ       Date:  1988-11-19

Review 8.  Optimum use of anticoagulants in pregnancy.

Authors:  J S Ginsberg; J Hirsh
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

9.  Risk of complications during intravenous heparin therapy.

Authors:  P H Nelson; K M Moser; C Stoner; K S Moser
Journal:  West J Med       Date:  1982-03

Review 10.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.